IV 
109TH CONGRESS 
1ST SESSION 
H. RES. 286 
Expressing the sense of the House of Representatives on promoting initiatives 
to develop an HIV vaccine. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 18, 2005 
Mr. VISCLOSKY (for himself, Mr. KING of New York, and Ms. LEE) submitted 
the following resolution; which was referred to the Committee on Inter-
national Relations 
RESOLUTION 
Expressing the sense of the House of Representatives on 
promoting initiatives to develop an HIV vaccine. 
Whereas more than 20,000,000 people have died of the ac-
quired immune deficiency syndrome (hereinafter referred 
to as ‘‘AIDS’’) between 1984 and 2004; 
Whereas AIDS claimed the lives of more than 3,000,000 peo-
ple in 2004, and nearly 8,500 people die each day from 
AIDS; 
Whereas an estimated 40,000,000 people around the world 
are living with the human immunodeficiency virus (here-
inafter referred to as ‘‘HIV’’) or AIDS; 
Whereas an estimated 14,000 people become infected with 
HIV every day;
•HRES 286 IH 
Whereas there will be 45,000,000 new HIV infections by 
2010 and nearly 70,000,000 deaths by 2020; 
Whereas an estimated 14,000,000 children have lost 1 or 
both parents to AIDS, and this number is expected to in-
crease to 25,000,000 by 2010; 
Whereas a child loses a parent to AIDS every 14 seconds; 
Whereas more than 90 percent of the people infected with 
HIV live in the developing world; 
Whereas more than 70 percent of the people infected with 
HIV live in sub-Saharan Africa; 
Whereas communities and countries are struggling with the 
devastating human and economic toll that HIV and 
AIDS has taken on them; 
Whereas the HIV/AIDS pandemic threatens political and re-
gional stability and has contributed to broader economic 
and social problems, including food insecurity, labor 
shortages, and the orphaning of generations of children; 
Whereas the United States is leading global efforts to combat 
the HIV/AIDS pandemic through its $15,000,000,000 
Emergency Plan for AIDS Relief and its commitment to 
the Global Fund to Fight AIDS, Tuberculosis and Ma-
laria; 
Whereas, through the World Health Organization, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS), 
and the Global Fund to Fight AIDS, Tuberculosis and 
Malaria, the international community is cooperating mul-
tilaterally to combat HIV/AIDS; 
Whereas developing an HIV vaccine is especially challenging 
due to the complicated nature of the virus;
•HRES 286 IH 
Whereas many biotechnology companies have not invested in 
the development of HIV vaccines; 
Whereas during the years 2001 and 2002, only 7 HIV vac-
cine candidates entered clinical trials, and only 1 of those 
candidates entered advanced human testing, but it proved 
ineffective; 
Whereas the International AIDS Vaccine Initiative (IAVI) 
has been a very effective and positive force in the devel-
opment of an HIV vaccine and has been instrumental in 
laying the groundwork for developing an HIV vaccine; 
Whereas the Bill and Melinda Gates Foundation, the Rocke-
feller Foundation, and other public and private organiza-
tions are pursuing a variety of initiatives to develop an 
HIV vaccine, including establishing BIO Ventures for 
Global Health to help small biotechnology companies ad-
dress the problems they confront in developing new med-
ical products for poor countries; 
Whereas, in June 2003, an international group of scientists 
proposed the creation of a Global HIV Vaccine Enter-
prise; 
Whereas, since that time the Global HIV Vaccine Enterprise 
has been established, creating an alliance of the world’s 
leading scientists and independent organizations com-
mitted to accelerating the development of a preventive 
HIV vaccine by enhancing coordination, information 
sharing, and collaboration globally; 
Whereas the members of the Group of Eight (Canada, 
France, Germany, Italy, Japan, Russia, the United King-
dom, and the United States) met in Sea Island, Georgia 
in June 2004 and reaffirmed their commitment to com-